Winslow Evans & Crocker’s Acceleron Pharma XLRN Stock Holding History

Winslow Evans & Crocker’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-1,616	Closed	-$80K	–	1149
2018 Q2	$80K	Hold	1,616	–	–	0.03%	411
2018 Q1	$63.1K	Sell	1,616 -84	-5%	-$3.57K	0.02%	440
2017 Q4	$72.1K	Hold	1,700	–	–	0.02%	423
2017 Q3	$63.4K	Hold	1,700	–	–	0.02%	434
2017 Q2	$51.7K	Buy	1,700 +440	+35%	+$12.8K	0.01%	550
2017 Q1	$33.4K	Hold	1,260	–	–	0.01%	624
2016 Q4	$32.2K	Hold	1,260	–	–	0.01%	635
2016 Q3	$45.6K	Hold	1,260	–	–	0.01%	559
2016 Q2	$42.8K	Sell	1,260 -140	-10%	-$4.55K	0.01%	548
2016 Q1	$36.9K	Buy	1,400 +400	+40%	+$11.6K	0.01%	566
2015 Q4	$48.8K	Hold	1,000	–	–	0.01%	537
2015 Q3	$24.9K	Hold	1,000	–	–	0.01%	666
2015 Q2	$31.6K	Buy	+1,000	New	+$32.3K	0.01%	656

Other funds holding XLRN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Winslow Evans & Crocker's XLRN Position: Q3 2018 in Review

Winslow Evans & Crocker sold out of Acceleron Pharma (XLRN) in Q3 2018, closing a stake of 1,616 shares — an estimated $80K sold.

Winslow Evans & Crocker first reported a position in XLRN in Q2 2015 and held it in 13 quarters. The position peaked at $80K in Q2 2018. 167 funds tracked by Wall St. Rank hold XLRN as of Q3 2018.

Winslow Evans & Crocker reported no remaining Acceleron Pharma position as of Q3 2018 after selling out during the quarter.
Winslow Evans & Crocker sold 1,616 Acceleron Pharma shares in Q3 2018, an estimated $80K.
Winslow Evans & Crocker first reported a position in Acceleron Pharma in Q2 2015 and held it in 13 quarters.
Winslow Evans & Crocker's Acceleron Pharma position peaked at $80K in Q2 2018.
167 funds tracked by Wall St. Rank held Acceleron Pharma as of Q3 2018.

Based on Winslow Evans & Crocker's 13F filing for Q3 2018, filed 15 Oct 2018.